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The objectives of these analyses were to assess the feasibility of the latest WHO recommendations (28-day
follow-up with PCR genotyping) for the assessment of antimalarial drug efﬁcacy in vivo and to examine how
different statistical approaches affect results. We used individual-patient data from 13 studies of uncompli-
cated pediatric falciparum malaria conducted in sub-Saharan Africa, using chloroquine (CQ), sulfadoxine/
pyrimethamine (SP), or amodiaquine (AQ). We assessed the use effectiveness and test performance of PCR
genotyping in distinguishing recurrent infections. In analyzing data, we compared (i) the risk of failure on
target days (days 14 and 28) by using Kaplan-Meier and per-protocol evaluable patient analyses, (ii) PCR-
corrected results allowing (method 1) or excluding (method 2) new infections, (iii) and day 14 versus day 28
results. Of the 2,576 patients treated, 2,287 (89%) were evaluable on day 28. Of the 695 recurrences occurring
post-day 14, 650 could be processed and 584 were resolved (PCR use effectiveness, 84%; test performance, 90%).
The risks of failure on day 28 with Kaplan-Meier and evaluable-patient analyses tended to be generally close
(except in smaller studies) because the numbers of dropouts were minimal, but attrition rates on day 28 were
higher with the latter method. Method 2 yielded higher risks of failure than method 1. Extending observation
to 28 days produced higher estimated risks of failure for SP and AQ but not for CQ (high failure rates by day
14). Results support the implementation of the current WHO protocol and favor analyzing PCR-corrected
outcomes by Kaplan-Meier analysis (which allows for dropouts) and retaining new infections (which minimizes
losses).
Malaria is one of the leading causes of morbidity and mor-
tality worldwide (14). The spread of parasite resistance to
ﬁrst-line drugs adds to the burden of the disease (9). A con-
tributing factor has been the continued use of failing drugs,
partly because of the difﬁculty of assessing their efﬁcacy in vivo.
Methodological issues still being debated include how long
patients should be monitored after treatment and whether
clinical or parasitological outcomes should be given greater
weight. Methods used so far differ greatly, making comparison
and synthesis of data very difﬁcult (16). The WHO has issued
different sets of guidelines, shifting emphasis with time from
parasitological (17) to clinical (18) assessment and more re-
cently recommending that patients be assessed both parasito-
logically and clinically and monitored for 28 days if true fail-
ures are to be distinguished from new infections; it also makes
provision for the use of life table analysis of results (19).
In areas of intense transmission, a second episode of malaria or
a recurrent parasitemia during the drug-free follow-up period
may be due to the same infection or a different infection (a
recrudescence, thus a treatment failure, or a new infection, re-
spectively). To distinguish these two events, polymorphic Plasmo-
dium falciparum genes, such as the merozoite surface protein 1
and 2 genes (msp1 and msp2) and the glutamate-rich protein
gene (glurp), can be genotyped by PCR (13). The duration of
follow-up required to capture all true treatment failures will
depend on a drug’s residence time in the body (15) and the
level of parasite sensitivity (21).
We analyzed data from 13 antimalarial drug studies with the
standard single-agent ﬁrst- and second-line drugs: chloroquine
(CQ), sulfadoxine/pyrimethamine (SP), and amodiaquine (AQ).
These studies enrolled 2,576 children in eight African coun-
tries from 2001 to 2004. The aims of this analysis were to (i)
determine the feasibility of in vivo assessment of antimalarial
drugs by using PCR genotyping for resolving recurrent infec-
tions (use effectiveness and test performance) and (ii) compare
current and alternative methods of data analysis. The current
recommendation is that failure rates should be calculated on
target days (days 14 and 28) by using PCR-corrected outcomes
after excluding both missing values and new infections (19).
Speciﬁcally, we wanted to compare (i) treatment outcomes
expressed as product limit estimates of failure (Kaplan-Meier)
versus per-protocol evaluable-patient analyses on target days
(days 14 and 28), (ii) analysis of PCR-corrected results allow-
ing or excluding new infections, and (iii) day 14 versus day 28
results.
* Corresponding author. Mailing address: Epicentre, 8 rue Saint
Sabin, 75011 Paris, France. Phone: (33) 140 21 28 06. Fax: (33) 140 21
28 03. E-mail: jguthmann@epicentre.msf.org.
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 MATERIALS AND METHODS
In vivo study methods. All 13 studies included in this analysis adhered to
current recommendations (19), with a few minor exceptions (see Results).
Brieﬂy, the children, aged 6 to 59 months and with consenting caregivers, were
eligible for enrolment if they had P. falciparum mono-infections (density thresh-
old at entry varied with endemicity at the study site; lower threshold, 500, 1,000,
or 2,000/l; upper threshold, 100,000 or 200,000/l), no signs of severity, no
reported hypersensitivities to the study drug, and no serious concomitant febrile
illnesses. We directly observed the intake of all doses (days 0, 1, and 2) and
reassessed the children clinically and parasitologically on days 2, 3, 7, 14, 21, and
28 or any day in between in the event of illness. When asymptomatic parasitemia
occurred after day 3, we monitored the children closely and administered a
rescue antimalarial (quinine) to those who had developed fever or were para-
sitemic on day 28. All studies underwent ethical review and were approved by the
relevant national authority.
We applied the WHO 2004 endpoint classiﬁcation (Table 1). When late-
clinical or parasitological failure occurred after day 14, we used PCR (2, 11, 12,
13) to compare the genotypic proﬁles of msp1 and msp2 for post- and pretreat-
ment parasites (in Bundi Bugyo, Uganda, glurp was also analyzed due to the low
allelic heterogeneity of local isolates). PCR analyses were conducted at Prince
Leopold Institute of Tropical Medicine, Antwerp, Belgium (four sites, 37% of
total samples); University of Glasgow, Glasgow, United Kingdom (three sites,
19% of total samples); Ho ˆpital Bichat, Paris, France (two sites, 15% of total
samples); Shoklo Malaria Research Unit, Mae Sod, Thailand (one site, 9% of
total samples); Kenya Medical Research Institute, Nairobi, Kenya, and Malaria
Research and Training Centre, Bamako, Mali (one site each, 8% of total sam-
ples); and Faculte ´d eM e ´dicine-Pharmacie, Rouen, France (one site, 4% of total
samples). Methods were not standardized across these laboratories, which used
different extraction methods, primers, and reaction conditions.
Cases in which pre- and posttreatment genotypes were identical were consid-
ered failures; cases in which pre- and posttreatment genotypes were different
were considered new infections; cases with mixed genotypes were classiﬁed as
failures. It is generally agreed that, contrary to epidemiological studies, the
persistence of pretreatment alleles after treatment indicates a failure to clear all
parasites. In the studies, there was no provision (except in Bundi Bugyo; see
above) for establishing the a priori diversity of the parasite population.
PCR genotyping. For each study, we identiﬁed cases requiring PCR genotyp-
ing, i.e., children with a recurrence after day 14 (it is generally assumed that, for
P. falciparum, recurrences on or before day 14 are recrudescences). These cases
were classiﬁed as either (i) resolved by PCR and further categorized as recru-
descences or new infections or (ii) unresolved by PCR, with the reason recorded
(missing sample, failure to extract DNA, or result not interpretable). PCR
genotyping was assessed in terms of (i) use effectiveness, deﬁned as the number
of cases resolved by PCR divided by the total number of children with recur-
rences after day 14 (the denominator includes missing samples), and (ii) test
performance, deﬁned as the number of cases resolved by PCR out of the total
number of paired samples available for genotyping (the denominator does not
include missing samples).
Failure rate (day 14 and day 28 evaluable-patient analysis) versus Kaplan-
Meier analysis. Failure rates at day 14 and day 28 were calculated using the
method of analysis recommended by the WHO (18) and compared to the prod-
uct limit estimates of failure obtained by Kaplan-Meier analysis. The WHO
method takes into account only patients with an outcome on the target day (day
14 or day 28) (evaluable patients). The Kaplan-Meier method allows for drop-
outs (losses during follow-up and withdrawals). In our Kaplan-Meier analysis,
the event measured was “failure” and the time to the event was the duration of
the follow-up (either 28 days for patients generating adequate clinical and par-
asitological response [ACPR] at day 28, x days for patients who failed at day x of
follow-up, or the number of days of follow-up until the last visit for patients lost
during follow-up or excluded). For both methods, we calculated the number of
patients included in the analysis and the risks of failure and compared these
ﬁgures between the two methods.
Day 28 PCR-corrected results for two methods of analysis. The WHO
currently recommend calculation of failure rates on target days by using
PCR-corrected outcomes after excluding both missing values and new infec-
tions (19).
We genotyped only recurrences occurring after day 14 and assumed all earlier
failures to be recrudescences. Two methods of analysis were used. For method 1,
all PCR-conﬁrmed new infections were reclassiﬁed as successes (ACPR), with
individuals unresolved by PCR excluded. For method 2, individuals with new
infections or infections unresolved by PCR were excluded from the analysis, per
the current WHO approach (19). For both methods, results are presented by
drug and study site as probabilities of failure [1  St, where St is probability of
survival] on day 28 with 95% conﬁdence intervals (CIs). Since recurrent episodes
occurring on or before day 14 were not genotyped, for day 14, we report only
crude (uncorrected) results (with no comparisons between data for methods 1
and 2).
Day 14 versus day 28 failures. Estimates of risk of failure by days 14 and 28
were analyzed separately (Table 1), based on results obtained with method 1 and
Kaplan-Meier analysis. Comparisons were expressed as absolute differences
(summarized across sites as medians and ranges). Correlations between day 14
and 28 results were expressed as coefﬁcients of correlation.
Data analysis was performed using Stata 8.2 (Stata Corp., College Station,
Texas).
RESULTS
Study proﬁles. The 13 studies analyzed children aged 6 to 59
months enrolled in 28 treatment arms in eight countries in
Africa between February 2001 and July 2004. Malaria was
hyperendemic in all sites except three (Table 2). All studies
were performed according to the latest WHO recommenda-
tions, with minor deviations at some sites (the lower limit of
parasitemia at entry was 1,000 parasites/l instead of 2,000 for
Bundi Bugyo; the upper limit of parasitemia at entry was
100,000 parasites/l instead of 200,000 for Bundi Bugyo,
Mapel, Caala, and Kuito; fever or history of fever in the pre-
vious 24 h instead of fever at entry was noted for Harper,
Caala, and Bundi Bugyo; and there was primary exclusion of
children with recent histories of antimalarial intake for Bundi
Bugyo, Harper, Caala, and Kuito).
Ten studies were compared: ﬁve studies (Angola Caala,
Chad Bongor, Sierra Leone Kabala, Sierra Leone Kailahun,
and Sierra Leone Makeni) compared all three drugs, three
TABLE 1. Efﬁcacy endpoints for WHO classiﬁcation
Endpoint
Criteria
Day 14 follow-up Day 28 follow-up
Early treatment failure Parasite density on day 2  that on day 0, parasite
density on day 3  25% that on day 0, fever in
the presence of parasites on day 3, or severe
malaria in the presence of parasites on days 1–3
Parasite density on day 2  that on day 0, parasite
density on day 3  25% that on day 0, fever in
the presence of parasites on day 3, or severe
malaria in the presence of parasites on days 1–3
Late clinical failure Fever in the presence of parasites between days 4
and 14 or severe malaria in the presence of
parasites between days 4 and 14
Fever in the presence of parasites between days 4
and 28 or severe malaria in the presence of
parasites between days 4 and 28
Late parasitological failure Parasites without fever on day 14 Parasites without fever on day 28
ACPR Follow-up completed without meeting any of the
above criteria
Follow-up completed without meeting any of the
above criteria
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 studies (Angola Kuito, DRC Boende, and Uganda Bundi
Bugyo) compared AQ and SP, and two studies (Mali Koumantou
and South Sudan Mapel) compared CQ and SP. Three studies
used single-arm AQ treatment (Liberia Harper, Sierra Leone
Freetown, and Sierra Leone Matru). All studies but two
(Angola Caala and Mali Koumantou) were nonrandomized
(patients enrolled in one treatment arm at a time).
Of the 9,610 patients screened (based on data available from
12 studies), 4,087 (42.3%) were slide positive; 2,576 (26.8%)
were treated with CQ (n  593), SP (n  989), or AQ (n 
994) (see Table 3 for details); 112 (4.3%) patients were lost
during follow-up (64 before day 14, 48 on or after day 14); and
177 (6.9%) were withdrawn (127 before day 14, 50 on or after
day 14). The characteristics of these patients on inclusion are
reported elsewhere (1, 3, 4–8, 10).
PCR ﬁndings. Among the total of 695 children with recur-
rent parasitemia after day 14, the question of recrudescence
versus new infection could not be resolved for 111 (16.0%),
either because at least one sample was missing (41%), because
DNA could not be extracted (18%), or because the result was
not interpretable (41%) (Table 2). Among the 584 children for
whom this question could be resolved, 334 (57%) had recru-
descences and 250 (43%) new infections. With the exception of
those for Bundi Bugyo (Uganda), infections were polyclonal
(six to eight alleles for msp1 and msp2). The use effectiveness
of PCR was 84% (584/695), and its test performance was 90%
(584/650). The median value for failure to genotype was 4%
(range, 0 to 33). There was no obvious difference between
laboratories in terms of test performance.
Risk of failure: per-protocol versus Kaplan-Meier analysis.
By day 14, 8% of the 2,576 children had been lost during fol-
low-up or withdrawn and are not included in the estimation of
risk of failure based on evaluable children, while with the Kaplan-
Meier method, only children with no follow-up (i.e., lost at day 0)
are not considered (1%) (Table 4). By day 28, 11% of enrolled
children had been lost during follow-up or withdrawn. After PCR
correction, the loss from the initial sample size was 6% for
Kaplan-Meier and 15% for day 28 evaluable-patient analysis
(method 1); losses were 15 and 25%, respectively, after removing
new infections (method 2).
Figure 1 shows the differences in sample size (percent dif-
ferences between data sets for Kaplan-Meier and evaluability
analyses) and estimated risk of failure (risk difference) on
day 28 (PCR corrected, with unresolved genotypes removed
[method 1] and unresolved genotypes and new infections both
removed [method 2]) for the two analyses. There were 256
TABLE 3. Estimated risk of failure for CQ, SP, and AQ on day 28,
calculated by Kaplan-Meier analysis using method 1 (unresolved
PCR excluded from the analysis) and method 2 (both
unresolved PCR and new infections excluded)
Drug Site
a % Day 28 failure (95% CI)
Difference
b
Method 1 Method 2
CQ Angola, Caala 81.2 (70.8–89.6) 82.8 (72.7–90.8) 1.6
Chad, Bongor 23.7 (16.1–34.0) 26.3 (18.0–37.4) 2.6
Mali, Koumantou 86.9 (79.5–92.6) 89.6 (82.7–94.7) 2.7
S.Leone, Kabala 44.2 (30.2–61.2) 52.8 (37.3–70.2) 8.6
S.Leone, Kailahun 87.5 (75.8–95.3) 90.4 (79.4–96.9) 2.9
S.Leone, Makeni 71.2 (56.2–84.7) 77.4 (62.6–89.5) 6.2
S.Sudan, Mapel 85.8 (76.3–92.8) 96.5 (89.5–99.3) 10.7
SP Angola, Caala 26.7 (18.3–37.9) 27.8 (19.1–39.4) 1.1
Angola, Kuito 34.9 (25.6–46.5) 35.4 (25.9–47.0) 0.5
Chad, Bongor 20.8 (14.1–30.1) 21.0 (14.3–30.4) 0.2
Mali, Koumantou 7.0 (3.4–14.1) 7.0 (3.4–14.1) 0%
DRC, Boende 39.0 (29.8–49.8) 45.2 (35.0–56.8) 6.2
S.Leone, Kabala 20.6 (12.9–32.0) 21.2 (13.2–32.8) 0.6
S.Leone, Kailahun 41.5 (31.7–53.0) 42.7 (32.7–54.3) 1.2
S.Leone, Makeni 24.0 (16.5–34.2) 26.1 (18.0–37.0) 2.1
S.Sudan, Mapel 15.6 (9.7–24.5) 17.0 (10.6–26.6) 1.4
Uganda, Bundi Bugyo 39.3 (29.6–50.9) 49.8 (38.3–62.6) 10.5
AQ Angola, Caala 17.3 (10.4–27.9) 18.8 (11.4–30.1) 1.5
Angola, Kuito 22.2 (14.9–32.3) 24.4 (16.4–35.2) 2.2
Chad, Bongor 8.4 (4.1–16.8) 8.5 (4.1–17.0) 0.1
Liberia, Harper 18.3 (11.0–29.6) 20.9 (12.6–33.3) 2.6
DRC, Boende 16.9 (10.5–26.5) 22.7 (14.4–34.8) 5.8
S.Leone, Freetown 5.5 (1.8–16.1) 5.9 (1.9–17.3) 0.4
S.Leone, Kabala 18.1 (10.7–29.9) 21.1 (12.5–34.3) 3.0
S.Leone, Kailahun 27.9 (18.7–40.4) 34.5 (23.5–48.8) 6.6
S.Leone, Makeni 4.8 (1.8–12.2) 5.9 (2.2–14.9) 1.1
S.Leone, Matru 13.2 (7.3–23.2) 15.6 (8.7–27.0) 2.4
Uganda, Bundi Bugyo 21.4 (13.0–34.0) 24.8 (15.2–38.9) 3.4
a S. Leone, Sierra Leone; S. Sudan, South Sudan.
b Result for method 2 minus result for method 1.
TABLE 2. Proﬁle of PCR genotyping of recurrent episodes of malaria during follow-up
Site (drugs)
a No. of recurrences
(needing genotyping)
No. of unresolved cases (PCR results not available) No. of resolved cases (PCR results available)
Total
(% recurrences)
Missing
sample No DNA Not
interpretable
Total
(% recurrences) Recrudescence New
infection
Angola, Caala (AQ, CQ, SP) 70 13 (18.6) 11 0 2 57 (81.4) 44 13
Angola, Kuito (AQ, SP) 55 6 (10.9) 4 2 0 49 (89.1) 35 14
Chad, Bongor
b (Q, CQ, SP) 38 16 (42.1) 5 11 0 22 (57.9) 11 11
Liberia, Harper (AQ) 27 4 (14.8) 4 0 0 23 (85.2) 11 12
Mali, Koumantou
b (CQ, SP) 54 3 (5.6) 3 0 0 51 (94.4) 47 4
DRC, Boende (AQ, SP) 97 3 (3.1) 1 1 1 94 (96.9) 43 51
Sierra L, Freetown (AQ) 8 2 (25.0) 2 0 0 6 (75.0) 2 4
Sierra L, Kabala (AQ, CQ, SP) 48 4 (8.3) 0 0 4 44 (91.7) 19 25
Sierra L, Kailahun (AQ, CQ, SP) 84 27 (32.1) 7 6 14 57 (67.9) 36 21
Sierra L, Makeni (AQ, CQ, SP) 74 14 (18.9) 4 0 10 60 (81.1) 25 35
Sierra L, Matru (AQ) 23 0 0 0 0 23 (100.0) 10 13
S. Sudan, Mapel (CQ, SP) 53 3 (5.7) 1 0 2 50 (94.3) 33 17
Uganda, B. Bugyo
b (AQ, SP) 64 16 (25.0) 3 0 13 48 (75.0) 18 30
Total 695 111 (16.0) 45 (40.5%) 20 (18.0%) 46 (41.4%) 584 (84.0) 334 (57.2%) 250 (42.8%)
a Sierra L, Sierra Leone; S. Sudan, South Sudan; B. Bugyo, Bundi Bugyo.
b Malaria is hyperendemic at all sites except these, where it is meso-endemic.
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 more patients in the data set for the Kaplan-Meier analysis
than in that for the evaluable-patient analysis (6%); propor-
tionally, with the larger sample used for method 1, the
difference between the results for the Kaplan-Meier and
evaluable-patient analyses was smaller with method 1 than
with method 2.
Failure rates were lower with the Kaplan-Meier analysis and
with method 2 in all studies but one (DRC Boende). Risk
differences ranged from 2.3% to 0.9% for CQ, 1.8% to
2.3% for SP, and 1.8% to 1.2% for AQ with method 1
and 9.7% to 0% for CQ, 2.2% to 0.2% for SP, and
1.5% to 0% for AQ with method 2.
Day 28 results for two methods of PCR analysis. Table 3
shows failure rates at day 28 estimated by Kaplan-Meier anal-
ysis with the two methods for analysis of PCR-corrected out-
comes. Method 2 (unresolved genotypes and new infections
removed) yields higher failure rates than method 1: 2.9
(range, 1.6 to 10.7) for CQ, 1.15 (range, 0 to 10.5) for
SP, and 2.4 (range, 0.1 to 6.6) for AQ.
Day 14 and day 28 Kaplan-Meier failure estimates. Because
method 1 minimizes the number of patients lost in the analysis,
we used it to compare risks of failure assessed at days 28 and
14 (Fig. 2); the median differences were 5.9% (range, 15.0
to 15.0) for CQ, 9.8% (range, 15.6 to 16.8) for SP, and
9.8% (range, 1.6 to 18.1) for AQ. The reason for the risk
of failure being lower in some instances on day 28 than on day
14 is that we compared outcomes for the analyses of two
different data sets (Table 1). Considering all studies, the coef-
ﬁcient of correlation was 0.94 between day 14 and day 28
results but was 0.89 for CQ, 0.67 for SP, and 0.50 for AQ.
DISCUSSION
There has been extensive discussion as to how efﬁcacy of
malaria treatment should be assessed, particularly in areas of
intense transmission. The “ideal”—follow-up sufﬁciently long
for all true treatment failures to emerge and be identiﬁed,
combined with the ability to discriminate correctly between
recrudescence and new infection in all cases—is currently un-
attainable. Getting as close as possible to the ideal presents
practical problems, especially concerning duration of post-
treatment follow-up (feasibility and risk of new infection pro-
portional to intensity of transmission), outcome measures
(clinical or parasitological criteria), and discrimination of re-
crudescence from new infection. The revised WHO protocol
with a 28-day follow-up and PCR genotyping of recurrent
infections addresses some shortcomings of earlier protocols.
However, questions are raised as to its feasibility in ﬁeld con-
ditions as well as optimal methods for analysis of PCR-cor-
rected outcomes.
We attempted to address a series of methodological issues
related to the evaluation of treatment outcomes in pediatric
uncomplicated malaria in Africa by analyzing 28 treatment
arms enrolling a total of 2,576 children on antimalarial mono-
therapy.
We found that, with suitable resources, the currently recom-
mended 28-day follow-up is feasible even in relatively prob-
TABLE 4. Patient attrition with the various analyses
a
Day Total no. of patients
enrolled (% lost)
No. of patients enrolled (% lost) for indicated analysis and method
Kaplan-Meier Per-protocol
Method 1 Method 2 No PCR
genotyping Method 1 Method 2 No PCR
genotyping
0 2,576
14 2,364 (8) 2,544 (1) 2,364 (8)
28 2,287 (11) 2,433 (6) 2,183 (15) 2,176 (15) 1,926 (25)
a Method 1 (cases unresolved by PCR excluded) and method 2 (cases unresolved by PCR and new infections both excluded) were applied to Kaplan-Meier and
evaluability (per-protocol) data sets after PCR genotyping. No genotyping was done until day 14.
FIG. 1. Comparison of Kaplan-Meier and evaluability (per-proto-
col) analyses (failure rates on day 28) using method 1 (PCR corrected,
with cases unresolved by PCR excluded) (open symbols) and method
2 (PCR corrected, with cases unresolved by PCR and new infections
both excluded) (closed symbols) by drug treatment.
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 lematical ﬁeld conditions (dropout rate, 5%; total exclusions
by day 28, 11%). Extending the period of observation from 14
to 28 days resulted in higher estimated risks of failure for SP
and AQ but not for CQ, for which the failure rates by day 14
were already extremely high. For AQ, the drug with the lowest
failure rates at day 14, the estimated failure rate was commonly
increased twofold or more when the follow-up was increased to
28 days. The gain in information varied with the drug and the
site (as a function of underlying levels of drug resistance and
transmission intensity, etc.).
This longer follow-up requires, however, that recurrent iso-
lates be genotyped. This too proved feasible and adequate in
these studies. Without PCR genotyping, 36% of the recurrent
parasitemias after day 14 (250/696 recurrences) would have
been wrongly classiﬁed as failures. This would have led to 1,048
cases being considered failures by day 28 (352 by or before day
14 plus 696 between days 14 and 28), thus overestimating the
risk of failure overall by about one-third. While not all recur-
rences could be ascribed to either a new infection or a recru-
descence (for 6%, a paired sample was not available, and for
an additional 10% of cases, genotypes could not be resolved
due to DNA extraction problems or because the result was not
interpretable), in these studies, PCR genotyping performed
very well (overall use effectiveness, 84%; test performance,
90%). Samples were genotyped in different laboratories by
using nonstandardized methods. While this may be seen as a
methodological deﬁciency, it makes these results representa-
tive of the variety of conditions applied in real life. In order to
optimize the use of PCR genotyping, it is important to calcu-
late the pretest probability of the same genotype occurring in
the same individual pre- and posttreatment.
We followed today’s prevailing practice of genotyping only
post-day 14 recurrences. However, we have (yet unpublished)
evidence from Uganda and Burkina-Faso that new infections
can be documented also pre-day 14. More research is needed
to further clarify the role and conditions under which PCR
genotyping should be done and analyzed, including the dis-
crimination power of PCR to correctly classify recurrent par-
asites.
A number of approaches are available for analysis of PCR-
corrected data. We compared current and alternative methods
of analyzing outcomes; our data set was large and heteroge-
neous. Given the high rates of follow-up and the high use
effectiveness of PCR achieved, the results obtained from the
different approaches were very similar in most instances, but
when the WHO protocol is applied in routine conditions, vari-
able dropout rates can be expected. Based on the principle that
one should discard as little information as possible, we favor
the use of Kaplan-Meier analysis in conjunction with treating
new infections as treatment successes (method 1). In our data,
this resulted in only 6% of patient data being lost for the entire
28-day study; by contrast, the current method (with patients
evaluable at target day and excluding new infections) results in
a substantial reduction in sample size (25%). This has conse-
quences for sample size calculations in studies, particularly
when dropout rates during follow-up are high (particularly if
follow-up is further extended for drugs with long half-lives). A
further extension to this approach, to avoid losing all the in-
formation provided by patients for whom PCR fails, would be
to use multiple imputation, and we believe that this is worthy
of further investigation. Indeed, there are pending issues with
the criteria used to ascribe a recurrent isolate to a new or
recrudescent infection.
Our results are in line with the WHO recommendation for
use of life tables in analyzing in vivo study results (19).
When comparing outcomes on days 14 and 28, the correla-
tion coefﬁcient calculated for all studies appears reasonable
but is misleading (inﬂuenced by the spread of data and the high
failure rates for CQ at both day 14 and day 28). There was poor
correlation with AQ. It should be noted that these analyses
pertain to single-agent treatments which are no longer recom-
mended. The WHO is now encouraging a review of drug policy
when PCR-corrected failure rates at day 28 exceed 10% and
the use of effective treatments, notably artemisinin-based com-
binations, including some with drugs with long residence times
FIG. 2. Failure rates (95% CIs) on day 14 (crude) (white bars) and
day 28 (PCR corrected, method 1) (gray bars) for chloroquine, sulfa-
doxine-pyrimethamine, and amodiaquine.
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 (20). The new policies will exacerbate the need for extended
follow-up and for accurate assessment of true failure rate.
In conclusion, our results support the implementation of the
latest WHO protocol (28-day follow-up with PCR genotyping),
which proved feasible in ﬁeld conditions. While this protocol is
more demanding for staff and carries extra costs, it is clear
that it provides a clearer picture of the level of resistance
than a follow-up of only 14 days, notably in the initial phase
of the establishment of resistance. To make maximum use of
the data, we favor analyzing PCR-corrected outcomes with
the Kaplan-Meier method and retaining new infections as
treatment successes.
ACKNOWLEDGMENTS
The original studies were conducted in collaboration with the Na-
tional Ministries of Health. We are grateful to MSF personnel at
headquarters and ﬁeld staff who actively contributed to the studies.
Special thanks to the Epicentre and MSF researchers responsible for
each individual study (Catherine Bachy, Maryline Bonnet, Francesco
Grandesso, Xavier de Radigue `s, Julia Sonia Ampuero, Vale ´rie Gabou-
laud, Paul Roddy, Guy Morineau, Martin de Smet, and Christa Hook).
We also thank the staffs of the different institutions who performed the
PCR analyses: Faculte ´d eM e ´decine-Pharmacie, Rouen, Ho ˆpital Bi-
chat, Paris, and Ho ˆpital Ambroise Pare ´, Boulogne, France; Prince
Leopold Institute of Tropical Medicine, Antwerp, Belgium; Malaria
Research and Training Centre, Bamako, Mali; University of Glasgow,
Glasgow, United Kingdom; and Shoklo Malaria Research Unit, Mae
Sod, Thailand. We thank Pascal Ringwald (WHO/RBM) for useful
discussion and exchange of information. Thank you to Nick White and
Kasia Stepniewska (Wellcome Trust, Mahidol University and Oxford
University) for critically reviewing the manuscript. Special thanks to
Emmanuel Baron, Head of the Medical Department of MSF-France,
for the support provided.
The individual studies were ﬁnanced by Me ´decins sans Frontie `res
and by Merlin in one of the sites in Sierra Leone. The present work is
a desk-based analysis, supported by Me ´decins sans Frontie `res.
The opinions expressed in this paper are the authors’ and do not
necessarily reﬂect those of the employing organizations.
REFERENCES
1. Bachy, C., F. Checchi, and P. Cavailler. 2003. Chloroquine and sulphadoxine-
pyrimethamine drug sensitivity study for the treatment of uncomplicated ma-
laria due to Plasmodium falciparum in Mapel, Sudan. Epicentre/MSF, Paris,
France.
2. Basco, L. K., and P. Ringwald. 2000. Molecular epidemiology of malaria in
Yaounde, Cameroon. VII. Analysis of recrudescence and reinfection in
patients with uncomplicated falciparum malaria. Am. J. Trop. Med. Hyg.
63:215–221.
3. Bonnet, M. 2004. Efﬁcacite ´ de la sulfadoxine-pyrime ´thamine, amodiaquine,
artesunate plus sulfadoxine-pyrime ´thamine et artesunate plus amodiaquine
pour le traitement du paludisme non-complique ´a ` Plasmodium falciparum,
dans le Centre de Sante ´ de Boende, Re ´publique De ´mocratique du Congo.
Epicentre/MSF Report, Paris, France.
4. Checchi, F., S. Balkan, B. T. Vonhm, M. Massaquoi, P. Biberson, P. Eldin de
Pecoulas, P. Brasseur, and J.-P. Guthmann. 2002. Efﬁcacy of amodiaquine
for uncomplicated Plasmodium falciparum malaria in Harper, Liberia.
Trans. R. Soc. Trop. Med. Hyg. 96:670–673.
5. Checchi, F., P. Piola, C. Kosack, E. Ardizzoni, D. Klarkowski, E. Kwezi, G.
Priotto, S. Balkan, N. Bakyaita, A. Brockman, and J.-P. Guthmann. 2004.
Antimalarial efﬁcacy of sulfadoxine-pyrimethamine, amodiaquine and a
combination of chloroquine plus sulfadoxine-pyrimethamine in Bundi
Bugyo, western Uganda. Trop. Med. Int. Health 9:445–450.
6. Checchi, F., P. Roddy, S. Kamara, A. Williams, G. Morineau, A. R. Wurie,
B. Hora, N. Lamotte, T. Baerwaldt, A. Heinzelmann, A. Danks, L. Pinoges,
A. Oloo, R. Durand, L. Ranford-Cartwright, and M. de Smet. 2005. Evidence
basis for antimalarial policy change in Sierra Leone: ﬁve in vivo efﬁcacy
studies of chloroquine, sulphadoxine-pyrimethamine and amodiaquine.
Trop. Med. Int. Health 10:146–153.
7. de Radigue `s, X., K. I. Diallo, P. A. Ngwakun, A. Djimde ´, O. Doumbo, M.
Diallo, M. van Herp, and J.-P. Guthmann. Submitted for publication.
8. Grandesso, F., C. Bachy, I. Donam, J. Ntambi, J. Habimana, U.
d’Alessandro, J. Maikere, V. Vanlerberghe, C. Hinzoumbe Kerah, and J.-P.
Guthmann. Efﬁcacy of chloroquine, sulfadoxine–pyrimethamine and amodi-
aquine for treatment of uncomplicated Plasmodium falciparum malaria in
Bongor and Koumra, Chad. Trans. R. Soc. Trop. Med. Hyg., in press.
9. Greenwood, B. M., K. Bojang, C. J. Whitty, and G. A. Targett. 2005. Malaria.
Lancet 365:1487–1498.
10. Guthmann, J.-P., J. Ampuero, F. Fortes, C. van Overmeir, V. Gaboulaud, S.
Tobback, J. Dunand, N. Saraiva, P. Gillet, J. Franco, A. Denoncin, M. van Herp,
S. Balkan, J.-C. Dujardin, U. D’Alessandro, and D. Legros. 2005. Antimalarial
efﬁcacy of chloroquine, amodiaquine, sulfadoxine-pyrimethamine, and the com-
binations of amodiaquine  artesunate and sulfadoxine-pyrimethamine 
artesunate in Huambo and Bie ´ provinces, central Angola. Trans. R. Soc. Trop.
Med. Hyg. 99:485–492.
11. Irion, A., I. Felger, S. Abdulla, T. Smith, R. Mull, M. Tanner, C. Hatz, and
H. P. Beck. 1998. Distinction of recrudescences from new infection by PCR-
RFLP analysis in a comparative trial of CGP 56 697 and chloroquine in
Tanzanian children. Trop. Med. Int. Health 3:490–497.
12. Ranford-Cartwright, L. C., J. Taylor, T. Umasunthar, L. H. Taylor, H. A.
Babiker, B. Lell, J. R. Schmidt-Ott, L. G. Lehman, D. Walliker, and P. G.
Kremsner. 1997. Molecular analysis of recrudescent parasites in a Plasmo-
dium falciparum drug efﬁcacy trial in Gabon. Trans. R. Soc. Trop. Med. Hyg.
91:719–724.
13. Snounou, G. 2002. Genotyping of Plasmodium spp. Nested PCR. Methods
Mol. Med. 72:103–116.
14. Snow, R. W., C. A. Guerra, A. M. Noor, H. Y. Myint, and S. I. Hay. 2005. The
global distribution of clinical episodes of Plasmodium falciparum malaria.
Nature 434:214–217.
15. Stepniewska, K., W. R. Taylor, M. Mayxay, R. Price, F. Smithuis, J.-P.
Guthmann, K. Barnes, H. Y. Myint, M. Adjuik, P. Olliaro, S. Pukrittayakamee,
S. Looareesuwan, T. T. Hien, J. Farrar, F. Nosten, N. P. Day, and N. J. White.
2004. In vivo assessment of drug efﬁcacy against Plasmodium falciparum ma-
laria: duration of follow-up. Antimicrob. Agents Chemother. 48:4271–4280.
16. Talisuna, A. O., P. Bloland, and U. D’Alessandro. 2004. History, dynamics,
and public health importance of malaria parasite resistance. Clin. Microbiol.
Rev. 17:235–254.
17. WHO. 1973. Chemotherapy of malaria and resistance to antimalarials. Re-
port of a WHO Scientiﬁc Group. WHO Tech. Rep. Ser. 529:1–21.
18. WHO. 1996. Assessment of therapeutic efﬁcacy of antimalarial drugs for
uncomplicated falciparum malaria in areas with intense transmission. Doc-
ument WHO/MAL/96.1077. World Health Organization, Geneva, Switzer-
land.
19. WHO. 2003. Assessment and monitoring of antimalarial drug efﬁcacy for the
treatment of uncomplicated falciparum malaria. Document WHO/HTM/
RBM/2003.50. World Health Organization, Geneva, Switzerland.
20. WHO. 2006. Guidelines for the treatment of malaria. Document WHO/
HTM/MAL/2006.1108. World Health Organization, Geneva, Switzerland.
[Online.] http://www.who.int/malaria/docs/TreatmentGuidelines2006.pdf.
21. Yeung, S., W. Pongtavornpinyo, I. M. Hastings, A. J. Mills, and N. J. White.
2004. Antimalarial drug resistance, artemisinin-based combination therapy,
and the contribution of modeling to elucidating policy choices. Am. J. Trop.
Med. Hyg. 71(Suppl. 2):179–186.
VOL. 50, 2006 METHODS IN THE ASSESSMENT OF ANTIMALARIAL TREATMENT 3739
 
b
y
 
o
n
 
S
e
p
t
e
m
b
e
r
 
7
,
 
2
0
0
7
 
a
a
c
.
a
s
m
.
o
r
g
D
o
w
n
l
o
a
d
e
d
 
f
r
o
m
 